FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2965862568> ?p ?o ?g. }

• W2965862568 abstract "Late-stage or recurrent intrahepatic cholangiocarcinoma (ICC) patients exhibit poor prognosis due to limited sensitivity to chemotherapy or radiotherapy and coexistence of multiple lesions. Programmed cell death protein 1 (PD-1) blockade provides a therapeutic opportunity for patients with high tumor mutation burden (TMB), high microsatellite instability (MSI-H), deficient mismatch repair (dMMR) and/or positive programmed cell death ligand 1 (PD-L1) expression. However, it is currently believed that patients with low TMB, microsatellite stable (MSS), proficient mismatch repair (pMMR) or negative PD-L1 expression are less likely to benefit from PD-1 blockade.Here we provide the first report on the therapeutic responses of ICC patients treated with combined PD-1 blockade with stereotactic body radiotherapy (SBRT) (Cyberknife) in the background of low TMB, MSS, pMMR and negative PD-L1 expression. One stage IVA ICC patients and two postsurgical recurrent ICC patients were involved in this study and the responses of both locally irradiated tumor(s) and the abscopal tumors or metastasis to the combined therapy were assessed by magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT). The stage IVA ICC patient (patient A) exhibited a TMB of 1.2 muts/Mb with MSS, pMMR and < 1% PD-L1 expression. Both the intrahepatic lesion and the lymph node metastases were well controlled for 7 months, and partial response (PR) was achieved with the sum of lesion diameters decreased by 40.9%. One of the postsurgical recurrent ICC patients (Patient B) exhibited a TMB of 3.8 muts/Mb with MSS, pMMR and < 1% PD-L1 expression. Both the recurrent intrahepatic lesion and the lymph node metastases were well controlled by the combined therapy and the sum of lesion diameter decreased by 86.3% (PR). The other postsurgical recurrent patient (Patient C) exhibited a TMB of 0.98 muts/Mb with MSS, pMMR and < 1% PD-L1 expression, and achieved complete response (CR) and maintained for 11 months. Abscopal effects were observed for all three patients.This study provided the first set of evidence for the effectiveness of SBRT and PD-1 blockade combined therapy in late-stage or recurrent ICC patients with low TMB, MSS, pMMR and negative PD-L1 expression, and potentially expanded the indications of the combined therapy to those patients who were previously not suitable for immunotherapy." @default.
• W2965862568 created "2019-08-13" @default.
• W2965862568 creator A5016048028 @default.
• W2965862568 creator A5023632317 @default.
• W2965862568 creator A5058228316 @default.
• W2965862568 creator A5078190129 @default.
• W2965862568 creator A5088688923 @default.
• W2965862568 creator A5089360026 @default.
• W2965862568 date "2019-08-05" @default.
• W2965862568 modified "2023-10-16" @default.
• W2965862568 title "Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade" @default.
• W2965862568 cites W133238296 @default.
• W2965862568 cites W1548034575 @default.
• W2965862568 cites W1844131367 @default.
• W2965862568 cites W1846437462 @default.
• W2965862568 cites W1892595029 @default.
• W2965862568 cites W1963570372 @default.
• W2965862568 cites W1970368087 @default.
• W2965862568 cites W1980180631 @default.
• W2965862568 cites W2022208959 @default.
• W2965862568 cites W2108789863 @default.
• W2965862568 cites W2164424438 @default.
• W2965862568 cites W2322658752 @default.
• W2965862568 cites W2337387091 @default.
• W2965862568 cites W2464620827 @default.
• W2965862568 cites W2557794937 @default.
• W2965862568 cites W2612419201 @default.
• W2965862568 cites W2617066209 @default.
• W2965862568 cites W2622499649 @default.
• W2965862568 cites W2728734704 @default.
• W2965862568 cites W2742841145 @default.
• W2965862568 cites W2747360078 @default.
• W2965862568 cites W2751602305 @default.
• W2965862568 cites W2780825854 @default.
• W2965862568 cites W2784868445 @default.
• W2965862568 cites W2787553571 @default.
• W2965862568 cites W2789601009 @default.
• W2965862568 cites W2789789184 @default.
• W2965862568 cites W2789813776 @default.
• W2965862568 cites W2794438152 @default.
• W2965862568 cites W2794662918 @default.
• W2965862568 cites W2805926640 @default.
• W2965862568 cites W2810229229 @default.
• W2965862568 cites W2901730862 @default.
• W2965862568 cites W2942836156 @default.
• W2965862568 cites W2947713225 @default.
• W2965862568 cites W3021696184 @default.
• W2965862568 cites W4211263016 @default.
• W2965862568 doi "https://doi.org/10.1186/s40425-019-0692-z" @default.
• W2965862568 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6683483" @default.
• W2965862568 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31383016" @default.
• W2965862568 hasPublicationYear "2019" @default.
• W2965862568 type Work @default.
• W2965862568 sameAs 2965862568 @default.
• W2965862568 citedByCount "55" @default.
• W2965862568 countsByYear W29658625682019 @default.
• W2965862568 countsByYear W29658625682020 @default.
• W2965862568 countsByYear W29658625682021 @default.
• W2965862568 countsByYear W29658625682022 @default.
• W2965862568 countsByYear W29658625682023 @default.
• W2965862568 crossrefType "journal-article" @default.
• W2965862568 hasAuthorship W2965862568A5016048028 @default.
• W2965862568 hasAuthorship W2965862568A5023632317 @default.
• W2965862568 hasAuthorship W2965862568A5058228316 @default.
• W2965862568 hasAuthorship W2965862568A5078190129 @default.
• W2965862568 hasAuthorship W2965862568A5088688923 @default.
• W2965862568 hasAuthorship W2965862568A5089360026 @default.
• W2965862568 hasBestOaLocation W29658625681 @default.
• W2965862568 hasConcept C104317684 @default.
• W2965862568 hasConcept C126322002 @default.
• W2965862568 hasConcept C126838900 @default.
• W2965862568 hasConcept C142724271 @default.
• W2965862568 hasConcept C143409427 @default.
• W2965862568 hasConcept C143998085 @default.
• W2965862568 hasConcept C170493617 @default.
• W2965862568 hasConcept C180754005 @default.
• W2965862568 hasConcept C185592680 @default.
• W2965862568 hasConcept C2775842073 @default.
• W2965862568 hasConcept C2778468042 @default.
• W2965862568 hasConcept C2779767149 @default.
• W2965862568 hasConcept C2781156865 @default.
• W2965862568 hasConcept C502942594 @default.
• W2965862568 hasConcept C509974204 @default.
• W2965862568 hasConcept C55493867 @default.
• W2965862568 hasConcept C61320498 @default.
• W2965862568 hasConcept C71924100 @default.
• W2965862568 hasConceptScore W2965862568C104317684 @default.
• W2965862568 hasConceptScore W2965862568C126322002 @default.
• W2965862568 hasConceptScore W2965862568C126838900 @default.
• W2965862568 hasConceptScore W2965862568C142724271 @default.
• W2965862568 hasConceptScore W2965862568C143409427 @default.
• W2965862568 hasConceptScore W2965862568C143998085 @default.
• W2965862568 hasConceptScore W2965862568C170493617 @default.
• W2965862568 hasConceptScore W2965862568C180754005 @default.
• W2965862568 hasConceptScore W2965862568C185592680 @default.
• W2965862568 hasConceptScore W2965862568C2775842073 @default.
• W2965862568 hasConceptScore W2965862568C2778468042 @default.
• W2965862568 hasConceptScore W2965862568C2779767149 @default.
• W2965862568 hasConceptScore W2965862568C2781156865 @default.
• W2965862568 hasConceptScore W2965862568C502942594 @default.

• next